14 Dec 2017 : Europe’s “strong international position” on the medical radioisotopes market is facing challenges, particularly in the form of new investment – preferably from the private sector – needed for ageing infrastructure, a report by the Nuclear Netherlands industry group says. The report says several European and non-European governments continue to subsidise different initiatives for Molybdenum-99 (Mo-99) production, thus putting pressure on the business case for private (...)